S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

$46.28
-0.15 (-0.32 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$45.43
Now: $46.28
$46.84
50-Day Range
$45.12
MA: $52.11
$57.29
52-Week Range
$36.69
Now: $46.28
$67.86
Volume437,163 shs
Average Volume1.09 million shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.47
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.74 per share

Profitability

Net Income$-240,920,000.00

Miscellaneous

Employees63
Market Cap$2.42 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.


Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings results on Friday, November, 1st. The company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

What price target have analysts set for BHVN?

13 brokerages have issued twelve-month target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $50.00 to $100.00. On average, they expect Biohaven Pharmaceutical's share price to reach $70.17 in the next year. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

What is the consensus analysts' recommendation for Biohaven Pharmaceutical?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

Has Biohaven Pharmaceutical been receiving favorable news coverage?

News stories about BHVN stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a news impact score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Biohaven Pharmaceutical.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Baidu (BIDU), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT) and Roku (ROKU).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Capital International Investors (5.59%), Oracle Investment Management Inc. (3.68%), State Street Corp (3.66%), Capital World Investors (3.15%), Capital International Inc. CA (2.18%) and Eagle Asset Management Inc. (1.43%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Marshall Wace LLP, Eagle Asset Management Inc., Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., State Street Corp, UBS Group AG and Schonfeld Strategic Advisors LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, John Tilton, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Point72 Asset Management L.P., Pictet Asset Management Ltd., Bluefin Trading LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rhenman & Partners Asset Management AB. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $46.28.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $2.42 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  331 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel